Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis

Therapeutic Innovation Australia 2026 Open access

Read full text

Authors: Therapeutic Innovation Australia

DOI: 10.82292/fbdd-8x59

Cited by: 0

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies SARS-CoV-2 detection and testing